Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

CT-P59

- PMLiVE

New coronavirus sees drug developers scramble to develop a vaccine

Researchers work to combat emerging threat

- PMLiVE

Mundipharma to launch first MabThera biosimilar in EU

EMA approves Truxima in all indications licensed to Roche’s cancer drug

Novartis building

Novartis takes biosimilar delay complaint to Supreme Court

Seeks to overturn US law that requires 180-day launch delay after regulatory approval

- PMLiVE

Study finds no problems switching from Remicade to biosimilar

Findings look to dispel ‘biosimilar resistance’ and encourage greater uptake

- PMLiVE

J&J is to appeal Remicade patent ruling in US

As Pfizer is poised to bring biosimilar version to market

- PMLiVE

Remicade safe from biosimilar competition this year, says J&J

Will defend the blockbuster’s US patents should Celltrion's Inflectra launch in 2016

- PMLiVE

FDA approves first Remicade biosimilar

Pfizer-Celltrion's Inflectra becomes the second biosimilar to be licensed in the US

- PMLiVE

FDA panel recommends first biosimilar antibody for approval

Pfizer to sell Celltrion's infliximab in the US pending FDA approval

- PMLiVE

Celltrion submits biosimilar Remicade for US approval

Drug is second to be assessed by FDA under biosimilars pathway

- PMLiVE

Herceptin could face biosimilars in UK later this year

Court overturns patents protecting Roche’s cancer drug

EU flag

First biosimilar mAb gets the nod in EU

Approval for Hospira's version of J&J's Remicade has global implications

- PMLiVE

First mAb biosimilars set for European approval

Celltrion and Hospira's versions of J&J's blockbuster Remicade recommended by CHMP

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links